XML 31 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Stockholders' Equity

11. STOCKHOLDERS’ EQUITY

Preferred Stock

The Company has 10 million shares of undesignated preferred stock authorized but not issued with rights and preferences determined by the Company’s Board of Directors at the time of issuance of such shares. As of March 31, 2021 and December 31, 2020, there were no shares of preferred stock issued and outstanding.

Common Stock

The Company has two classes of authorized common stock, Class A common stock and Class B common stock. Holders of Class A common stock are entitled to one vote for each share of Class A common stock held on all matters submitted to a vote of stockholders and holders of Class B common stock are entitled to ten votes for each share of Class B common stock held on all matters submitted to a vote of stockholders. Except with respect to voting, the rights of the holders of Class A and Class B common stock are identical. Shares of Class B common stock are voluntarily convertible into shares of Class A common stock at the option of the holder and are generally automatically converted into shares of the Company's Class A common stock upon sale or transfer. Shares issued in connection with exercises of stock options, vesting of restricted stock units, or shares purchased under the employee stock purchase plan are generally automatically converted into shares of the Company’s Class A common stock.

At-the-Market Offering

On March 2, 2021, the Company entered into an Equity Distribution Agreement with Morgan Stanley & Co. LLC, Citigroup Global Markets Inc. and Evercore Group L.L.C., as its sales agents, pursuant to which the Company could offer and sell from time-to-time shares of its Class A common stock for aggregate gross proceeds of up to $1,000.0 million. In

March 2021, the Company sold approximately 2.6 million shares of Class A common stock at an average selling price of $379.26 per share, for aggregate gross proceeds of $1,000.0 million and incurred issuance costs of $10.4 million.

Common Stock Reserved For Future Issuance

At March 31, 2021, the Company had reserved shares of common stock for issuance as follows (in thousands):

 

 

 

As of March 31, 2021

 

Common stock awards granted under equity incentive plans

 

 

11,457

 

Common stock awards available for issuance under the 2017 Employee Stock Purchase Plan *

 

 

5,089

 

Common stock awards available for issuance under the 2017 Equity Incentive Plan

 

 

27,847

 

Total reserved shares of common stock

 

 

44,393

 

 

* The Company has not issued any common stock pursuant to the 2017 Employee Stock Purchase Plan.

Equity Incentive Plans

The Company has two equity incentive plans, the 2008 Equity Incentive Plan (the “2008 Plan”) and the 2017 Equity Incentive Plan (the “2017 Plan”). The 2017 Plan became effective September 2017 in connection with the Company’s initial public offering. No further shares have been issued under the 2008 Plan. The 2017 Plan provides for the grant of incentive stock options to the Company’s employees and for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards, and other forms of equity compensation to the Company’s employees, directors and consultants.

Restricted stock units granted under the plan are subject to continuous service. Options granted under the plans are granted at a price per share equivalent to the fair market value on the date of grant. Recipients of option grants who possess more than 10% of the combined voting power of the Company (a “10% Shareholder”) are subject to certain limitations, and incentive stock options granted to such recipients are at a price no less than 110% of the fair market value at the date of grant.

Restricted Stock Units

Restricted stock unit activity for the three months ended March 31, 2021 is as follows (in thousands, except per share data):

 

 

Number of

Shares

 

 

Weighted Average

Grant Date Fair

Value Per Share

 

Balance, December 31, 2020

 

 

4,355

 

 

$

92.91

 

Awarded

 

 

97

 

 

 

384.11

 

Released

 

 

(387

)

 

 

71.77

 

Forfeited

 

 

(71

)

 

 

112.86

 

Balance, March 31, 2021 – outstanding

 

 

3,994

 

 

$

101.66

 

The grant-date fair value of restricted stock units granted during the three months ended March 31, 2021 and 2020 was $37.2 million and $53.6 million, respectively. The grant-date fair value of restricted stock units that vested during the three months ended March 31, 2021 and 2020 was $27.8 million and $17.1 million, respectively. Total unrecognized compensation cost related to restricted stock units as of March 31, 2021 was $330.7 million, which the Company expects to recognize over a weighted-average period of approximately 2.11 years.

Stock Options

The following table summarizes the Company’s stock option activities under the 2008 Plan and 2017 Plan (in thousands, except per share data):

 

 

Number of

Shares

 

 

Weighted

Average

Exercise

Price

 

 

Weighted

Average

Remaining

Contractual

Life (Years)

 

 

Weighted

Average

Grant Date

Fair Value

Per Share

 

 

Aggregate

Intrinsic

Value

 

Balance, December 31, 2020

 

 

8,733

 

 

$

26.19

 

 

 

5.7

 

 

 

 

 

 

 

 

Granted

 

 

10

 

 

 

413.11

 

 

 

 

 

$

154.43

 

 

 

 

 

Exercised

 

 

(1,276

)

 

 

5.25

 

 

 

 

 

 

 

 

 

 

 

Forfeited and expired

 

 

(4

)

 

 

7.57

 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2021 - outstanding

 

 

7,463

 

 

$

30.31

 

 

 

5.8

 

 

 

 

 

$

2,206,030

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options exercisable at March 31, 2021

 

 

5,311

 

 

$

9.47

 

 

 

4.9

 

 

 

 

 

$

1,680,001

 

The weighted average grant-date fair value of options granted during the three months ended March 31, 2021 and 2020, was $154.43 and $42.17, respectively. The intrinsic value for options exercised in the three months ended March 31, 2021 and 2020, was $494.1 million and $52.7 million, respectively. Intrinsic value represents the difference between the fair values of the Company’s common stock and the options’ exercise price on the date of grant.

As of March 31, 2021, the Company had $44.8 million of unrecognized stock compensation expense related to unvested stock options that is expected to be recognized over a weighted-average period of approximately 1.79 years.

Stock-Based Compensation

The Company measures the cost of employee services received in exchange for an equity award based on the grant date fair value of the award. Generally, stock options granted to employees vest 25% after one year and then 1/48th monthly thereafter and have a term of ten years. Restricted stock units generally vest over 4 years. For the three months ended March 31, 2021 and 2020, the amount of stock-based compensation capitalized as part of internal use software was not material.

The following table shows total stock-based compensation expense for the three months ended March 31, 2021 and 2020 (in thousands):

 

 

Three Months Ended

 

 

 

March 31, 2021

 

 

March 31, 2020

 

Cost of platform revenue

 

$

198

 

 

$

211

 

Cost of player revenue

 

 

415

 

 

 

338

 

Research and development

 

 

16,554

 

 

 

13,255

 

Sales and marketing

 

 

13,363

 

 

 

10,057

 

General and administrative

 

 

10,007

 

 

 

6,544

 

Total stock-based compensation

 

$

40,537

 

 

$

30,405

 

 

The fair value of options granted under the equity incentive plans is estimated on the grant date using the Black-Scholes option-valuation model. The assumptions used in the Black-Scholes model are as follows:

 

 

Three Months Ended

 

 

 

March 31, 2021

 

 

March 31, 2020

 

Expected term (in years)

 

5.0 - 6.0

 

 

 

5.0

 

Risk-free interest rate

 

0.36 - 0.80%

 

 

0.88 - 1.67%

 

Expected volatility

 

38.3 - 39.0%

 

 

 

36.0

%

Dividend rate